Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
Open Access
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 29 (2) , 873-885
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- National Institutes of Health (OT2R002514)
- National Institutes of Health (1U01CA207160)
- National Center for Advancing Translational Sciences
This publication has 41 references indexed in Scilit:
- High-Throughput Methods for Combinatorial Drug DiscoveryScience Translational Medicine, 2013
- Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in HumansAntimicrobial Agents and Chemotherapy, 2013
- Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad Antiviral EffectsPLOS Pathogens, 2012
- Existing and Developing Approaches for QSAR Analysis of MixturesMolecular Informatics, 2012
- Best Practices for QSAR Model Development, Validation, and ExploitationMolecular Informatics, 2010
- The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole Is Highly Synergistic with HCV Protease InhibitorsThe Journal of Infectious Diseases, 2010
- Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling ResearchJournal of Chemical Information and Modeling, 2010
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Beware of q2!Journal of Molecular Graphics and Modelling, 2002
- Intracellular distribution and effect of the antimalarial drug mefloquine on lysosomes of rat liverLiver International, 1992